Balefire LLC Purchases New Stake in Zoetis Inc. $ZTS

Key Points

• Balefire LLC acquired 2,379 shares of Zoetis Inc. for approximately $371,000 during the second quarter.
• Several institutional investors have increased their stakes in Zoetis, with hedge funds now owning 92.80% of the company's stock.
• Analysts have mixed views on Zoetis, with price targets ranging from $155.00 to $215.00, averaging at $200.88 for the stock.

Balefire LLC purchased a new stake in Zoetis Inc. (NYSE:ZTS - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 2,379 shares of the company's stock, valued at approximately $371,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Nova Wealth Management Inc. bought a new position in shares of Zoetis during the first quarter valued at $25,000. 1248 Management LLC bought a new position in Zoetis during the 1st quarter valued at about $27,000. Saudi Central Bank bought a new position in Zoetis during the 1st quarter valued at about $29,000. Cornerstone Planning Group LLC raised its stake in shares of Zoetis by 79.3% in the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock valued at $30,000 after acquiring an additional 88 shares during the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. raised its stake in shares of Zoetis by 87.6% in the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company's stock valued at $42,000 after acquiring an additional 120 shares during the last quarter. 92.80% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

ZTS has been the subject of a number of research analyst reports. Leerink Partners cut shares of Zoetis from an "outperform" rating to a "market perform" rating and cut their target price for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Argus reiterated a "buy" rating and issued a $190.00 price objective on shares of Zoetis in a research report on Tuesday, September 9th. Stifel Nicolaus cut Zoetis from a "buy" rating to a "hold" rating and cut their price target for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Leerink Partnrs cut Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. Finally, Piper Sandler boosted their price objective on shares of Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research report on Monday, August 11th. Five equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $200.88.

Zoetis Trading Up 0.2%

Shares of ZTS stock traded up $0.23 on Thursday, reaching $147.16. The company had a trading volume of 2,739,409 shares, compared to its average volume of 2,257,212. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. The stock has a market cap of $65.22 billion, a PE ratio of 25.33, a PEG ratio of 2.36 and a beta of 0.89. The company has a 50-day moving average of $151.43 and a 200-day moving average of $156.76. Zoetis Inc. has a 12 month low of $139.70 and a 12 month high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating analysts' consensus estimates of $1.62 by $0.14. The business had revenue of $2.46 billion during the quarter, compared to analysts' expectations of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm's quarterly revenue was up 4.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.